The 2007 ACC/AHA Guidelines for management of patients with unstable angina and non-STEMI were just released. They once again suggest the use of abciximab (Reopro) as the preferred glycoprotein receptor antagonist in patients that are going for PCI. If there is an anticipated delay to PCI, then eptifibatide (Integrilin) or tirofiban (Aggrastat) are preferred. The best evidence for these medications is in patients being managed invasively rather than just medically.
